$8.09
5.06% yesterday
NYSE, Sep 27, 10:10 pm CET
ISIN
US37611X1000
Symbol
DNA

Ginkgo Bioworks Stock price

$8.09
+0.56 7.44% 1M
-35.91 81.61% 6M
-59.51 88.03% YTD
-63.11 88.64% 1Y
-523.11 98.48% 3Y
-396.71 98.00% 5Y
-396.71 98.00% 10Y
NYSE, Closing price Fri, Sep 27 2024
+0.39 5.06%
ISIN
US37611X1000
Symbol
DNA
Sector

Key metrics

Market capitalization $404.83m
Enterprise Value $124.38m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.67
P/S ratio (TTM) P/S ratio 2.20
P/B ratio (TTM) P/B ratio 0.45
Revenue growth (TTM) Revenue growth -43.45%
Revenue (TTM) Revenue $184.34m
EBIT (operating result TTM) EBIT $-641.65m
Free Cash Flow (TTM) Free Cash Flow $-346.60m
Cash position $732.72m
EPS (TTM) EPS $-18.03
P/E forward negative
P/S forward 2.18
EV/Sales forward 0.67
Short interest 22.92%
Show more

Is Ginkgo Bioworks a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Ginkgo Bioworks Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Ginkgo Bioworks forecast:

1x Buy
17%
1x Hold
17%
4x Sell
67%

Analyst Opinions

6 Analysts have issued a Ginkgo Bioworks forecast:

Buy
17%
Hold
17%
Sell
67%

Financial data from Ginkgo Bioworks

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
184 184
43% 43%
100%
- Direct Costs 101 101
42% 42%
55%
83 83
45% 45%
45%
- Selling and Administrative Expenses 169 169
74% 74%
91%
- Research and Development Expense 484 484
31% 31%
262%
-569 -569
52% 52%
-309%
- Depreciation and Amortization 72 72
24% 24%
39%
EBIT (Operating Income) EBIT -642 -642
50% 50%
-348%
Net Profit -898 -898
27% 27%
-487%

In millions USD.

Don't miss a Thing! We will send you all news about Ginkgo Bioworks directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ginkgo Bioworks Stock News

Neutral
PRNewsWire
4 days ago
BOSTON and CHESTERFIELD, Mo. , Sept. 24, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced its new partnership with NOVUS International, an innovator and leader in intelligent nutrition, to develop advanced feed additives designed to meet the evolving needs of the animal agriculture industry.
Neutral
PRNewsWire
10 days ago
BOSTON , Sept. 18, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient.
Positive
The Motley Fool
10 days ago
The biotech rolled out two new healthtech innovations. One is a large language model (LLM) developed with its partner Alphabet.
More Ginkgo Bioworks News

Company Profile

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Head office United States
CEO Jason Kelly
Employees 1,218
Founded 2008
Website www.ginkgobioworks.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today